Chimeric Polypeptides for Bacterial Decolonization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bacterial infections, particularly those caused by antibiotic-resistant bacteria like MRSA, face challenges due to the need for high concentrations of bacteriophage-derived endolysins, which are unstable and less effective in complex matrices, leading to resistance issues and inefficiencies.
Innovation Solution
Development of chimeric polypeptides combining bacteriocin cell binding domains with enzymatic active domains from bacteriophage lysins or bacterial autolysins, enhancing stability, solubility, and specificity to target Gram-positive bacteria like Staphylococcus aureus, including MRSA, with improved activity and reduced resistance potential.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high concentrations of bacteriophage-derived endolysins are used to treat bacterial infections, then bacterial killing activity is improved, but stability and effectiveness in complex matrices deteriorates
Solution Approach 1:
The patent creates chimeric polypeptides by fusing the enzymatic active domain (EAD) of bacteriophage lysins with the cell binding domain (CBD) of bacteriocins. This composite structure combines the bactericidal activity of lysins with the enhanced stability and specificity of bacteriocins, resulting in a molecule that maintains high bacterial killing activity while exhibiting improved stability in complex matrices such as serum and body fluids.
Solution Approach 2:
The invention modifies the molecular structure parameters of endolysins by replacing or fusing their native cell binding domains with bacteriocin CBDs. This parameter change in the protein structure fundamentally alters the stability profile and matrix compatibility of the enzyme, allowing it to function effectively at lower concentrations in complex biological environments.
2Stability of the object's composition
If bacteriocin cell binding domains are fused with enzymatic active domains to create chimeric polypeptides, then stability and specificity are improved, but device complexity increases
Solution Approach 1:
The chimeric polypeptide is divided into two functional segments: the N-terminal bacteriocin CBD segment that provides stability and specificity, and the C-terminal lysin EAD segment that provides bactericidal activity. This segmentation allows each domain to perform its specialized function while being part of a unified protein structure, simplifying the understanding and production of the chimeric molecule.
Solution Approach 2:
The patent merges two previously separate functional domains (bacteriocin CBD and lysin EAD) into a single chimeric polypeptide molecule. This merging creates a unified therapeutic agent that simultaneously provides the stability of bacteriocins and the killing activity of lysins, reducing the need for separate administration of multiple agents.
3Reliability
If conventional antibiotic decolonisation regimens are used, then bacterial eradication is achieved, but resistance development and opportunistic infections increase
Solution Approach 1:
The patent converts the narrow specificity of bacteriocins, which was traditionally a limitation for broad-spectrum coverage, into a beneficial feature. By using bacteriocin CBDs that specifically target pathogenic bacteria like S. aureus while sparing commensal flora, the therapy achieves effective decolonization without the harmful side effects of broad-spectrum antibiotics, including resistance development and opportunistic infections.
Solution Approach 2:
The chimeric polypeptide acts as an intermediary between the specific targeting capability of bacteriocins and the potent killing mechanism of lysins. This intermediary structure enables selective eradication of pathogenic bacteria while leaving beneficial microbiota intact, thereby preventing the development of resistance and avoiding opportunistic infections associated with broad-spectrum antibiotic use.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The chimeric polypeptides demonstrate enhanced efficacy with lower MIC and MBC values, improved thermal stability, and specificity for target bacteria, effectively reducing bacterial colonization and infection without interfering with normal flora, and are stable in complex matrices.
Implementation Method 1
one domain that confers binding specificity to a carbohydrate epitope of the cell wall (cell binding domain—CBD)
Implementation Method 2
at least one domain that confers the enzymatic activity for hydrolysing specific bonds in the murein or peptidoglycan layer of the bacterial cell wall (enzymatic active domain—EAD)
Data Source
AI summary
The present invention relates to assays, kits and oligonucleotides for the detection of Pseudomonas aeruginosa for a fast, sensitive and reliable detection of Pseudomonas aeruginosa in a species- and serotype-specific manner. In particular, the present invention provides an assay for the serotype-specific detection of Pseudomonas aeruginosa, a kit for the serotype-specific detection of Pseudomonas aeruginosa, as well as oligonucleotides useful in such assay or kit. The present invention further relates to the use of Pseudomonas aeruginosa serotype specific antibodies for serotype specific treatment of Pseudomonas aeruginosa infection in a patient detected for said specific Pseudomonas aeruginosa serotype with such an assay or kit.